Stem Cells Market (Product Type: Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell, and Others; Source: Autologous and Allogenic; Application: Regenerative Medicines [Neurology, Oncology, Cardiology, and Others] and Drug Discovery & Development; and End-user: Therapeutics Companies, Cell & Tissue Banks, Tools & Reagents Companies, and Service Companies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2030

Stem Cells Market Outlook 2028

The global stem cells market was valued over US$ 11.73 Bn in 2020

It is estimated to expand at a CAGR of 10.4% from 2021 to 2030

The global stem cells market is expected to reach the value of US$ 25.68 Bn by the end of 2030

Analysts’ Viewpoint on Stem Cells Market Scenario

Stem cells are used in treating various illnesses in the body. Technological advancements in healthcare and pharmaceutical industries are creating potential revenue opportunities for market players operating in the stem cells market. Increasing investments in R&D activities to explore innovative ways to use stem cells for different healthcare applications are driving the global stem cells market. The growing incidences of diseases such as cancer, diabetes, and heart diseases boost the demand for stem cells. Market players are exploring new approaches to culturing or utilizing stem cells in various applications. Rapid expansion of pharmaceutical companies and clinical research institutes in developed regions is fueling the growth of the market. High cost is a major factor affecting the growth of the global stem cells market. Companies in the stem cells market should experiment with new techniques to improvise the testing processes.

Increasing Demand for Stem Cells in Regenerative Medicines Accelerates Market Growth

The global stem cells market is majorly driven by rising applications of stem cells in regenerative medicines. Increase in the number of chronic diseases such as cardiac diseases, diabetes, cancer, etc. across the globe is responsible for market growth. Regenerative medicines are used in the treatment of various diseases, and are made using stem cells in order to repair an injured tissue. The rising clinical trials for regenerative medicines, along with increasing development in stem cell-based therapies is the factor creating value-grab opportunities for the market players. Companies operating in the global stem cells market are conducting basic research and preclinical trials for testing the regenerative capacity of stem cells in the treatment of various neurological conditions. With consistent efforts of scientists and R&D activities in stem cell biologics, market players are gaining lucrative growth opportunities in the global market.

Rising Healthcare Expenditure and Increasing Investment in R&D Activities

There has been a lot of research & development activities in the field of stem cells biologics. The high demand for stem cells in therapeutic treatments for neurological disorders, cancer, heart diseases, diabetes, etc. is driving the global market, creating lucrative revenue opportunities for manufacturers in the stem cells market. Governments are taking steps to support pharmaceutical companies, and investing in research and development activities. Manufacturers are bolstering their R&D capabilities to experiment with new technologies and applications. Manufacturers operating in the global stem cells market are using technological innovations to stay ahead of the competition and generate more revenue opportunities. Increasing healthcare expenditure, research & development activities, and trending advances in biologics strengthen the scope and expansion of the stem cells market.

Increase in Funding for Stem Cell Research Generates Potential Opportunities

Increasing applications of stem cells for many health conditions and chronic diseases that affect millions of people globally. Consistent research in the field of stem cells is one of the key factors driving the growth of the market. Funding provided by governments and other private organizations to carry out extensive research on stem cells are encouraging market stakeholders to pave their ways in the global market by providing treatment for various chronic illnesses. The stem cells market is expected to witness abundance of growth opportunities in the upcoming years. The increasing number of chronic illnesses is anticipated to revive the growth of the stem cells market.

North America Market Players Offering Profitable Revenue Opportunities

North America is expected to account for a major share of the global stem cells market during the forecast period. The North America stem cells market is majorly driven by increasing prevalence of lifestyle diseases such as diabetes, cancer, heart diseases, etc. in the region. In addition, technological advancements in healthcare, increasing investment on research & development activities, and growing number of diagnostic facilities are some of the key factors fueling market growth in North America. Manufacturers operating in the stem cells market are shifting toward electronics medical devices to increase the performance of services. Countries in Asia Pacific such as China and India are responsible for the fastest growth of the stem cells market in the region. Moreover, rapid urbanization and increasing spending on healthcare are factors contributing to the market growth in Asia Pacific.

Stem Cells Market: Overview

The global stem cells market for the historical period 2017–2019 and forecast period 2021–2028, Increasing health care expenditure in developing countries is projected to drive the global stem cells market during the forecast period

Increase in Funding for Stem Cell Research: Key Driver

Stem cells hold the promise for treatments and cures of more than 70 major diseases and conditions that affect millions of people globally. Several private and government sectors support funding for stem cell research.

According to Change.org, Inc., in the U.S., 64% of the people support federal funding of research on chronic diseases using stem cells taken from human embryos

Internationally, stem cell research is supported by significant government investments, with Asia being one of the most favorable regions. Stem cell research funding by the National Institutes of Health (NIH) has been increasing in the past few years.

Rise in Stem Cell Banking Services to Boost Market Growth

Umbilical cord blood provides a pool of hematopoietic and mesenchymal stem cells, which can be stored after childbirth for later use. The stored blood finds applications in treatment of hematological disorders such as leukemia, lymphoma, and sickle cell anemia.

The cost of storage is high, and according to the American Academy of Pediatrics, the odds that a person will require cord blood stem cells are 1:1,000

Nevertheless, parents opt for the storage and over 20,000 people in the U.S. have undergone surgeries, which have utilized stored umbilical cord blood

High Treatment Cost to Hamper Market

Stem cell treatment is expensive; major proportion of the global population cannot afford it

For instance, a full treatment with Prochymal, a stem cell-based drug approved in Canada to alleviate pediatric rejection of bone marrow transplants, is estimated to cost around US$ 200,000

This substantiates the fact that only a small proportion of population of the world is capable of spending on stem cell therapies

Stem Cells Market: Competition Landscape

This report profiles major players in the global stem cells market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global stem cells market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global stem cells market are

• STEMCELL Technologies, Inc.
• Astellas Pharma, Inc.
• Cellular Engineering Technologies, Inc.
• BioTime, Inc.
• Takara Bio, Inc.
• U.S. Stem Cell, Inc.
• BrainStorm Cell Therapeutics, Inc.
• Cytori Therapeutics, Inc.
• Osiris Therapeutics, Inc.
• Caladrius Biosciences, Inc., among others

Key Questions Answered in Stem Cells Market Report

• What is the scope of growth of product companies in the global stem cells market?
• What will be the Y-o-Y growth of the global stem cells market between 2017 and 2028?
• What is the influence of changing trends in technologies on the global stem cells market?
• Will North America be the most profitable market for stem cells devices providers?
• Which factors are anticipated to hamper the growth of the global stem cells market during the forecast period?
• Which are the leading companies in the global stem cells market?

Stem Cells Market – Segmentation

Product Type

• Adult Stem Cell
• Human Embryonic Stem Cell
• Induced Pluripotent Stem Cell
• Others

Source

• Autologous
• Allogenic

Application

• Regenerative Medicines
• Neurology
• Oncology
• Cardiology
• Others
• Drug Discovery & Development

End-user

• Therapeutics Companies
• Cell & Tissue Banks
• Tools & Reagents Companies
• Service Companies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Stem Cells Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Stem Cells Market Analysis and Forecast, 2017–2028

        4.4.1. Market Revenue Projections (US$ Mn)

        4.4.2. Market Volume/Unit Shipments Projections

5. Key Insights

    5.1. Disease Prevalence & Incidence Rate globally with key countries

    5.2. Key Industry Developments

    5.3. Pipeline Analysis

    5.4. COVID-19 Impact Analysis

6. Global Stem Cells Market Analysis and Forecast, by Product Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product Type, 2017–2028

        6.3.1. Adult Stem Cell

        6.3.2. Human Embryonic Stem Cell

        6.3.3. Induced Pluripotent Stem Cell

        6.3.4. Others

    6.4. Market Attractiveness Analysis, by Product Type

7. Global Stem Cells Market Analysis and Forecast, by Source

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Source, 2017–2028

        7.3.1. Autologous

        7.3.2. Allogenic

    7.4. Market Attractiveness Analysis, by Source

8. Global Stem Cells Market Analysis and Forecast, by Application

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Application, 2017–2028

        8.3.1. Regenerative Medicines

            8.3.1.1. Neurology

            8.3.1.2. Oncology

            8.3.1.3. Cardiology

            8.3.1.4. Others

        8.3.2. Drug Discovery & Development

    8.4. Market Attractiveness Analysis, by Application

9. Global Stem Cells Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by End-user, 2017–2028

        9.3.1. Therapeutics Companies

        9.3.2. Cell & Tissue Banks

        9.3.3. Tools & Reagents Companies

        9.3.4. Service Companies

    9.4. Market Attractiveness Analysis, by End-user

10. Global Stem Cells Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Country/Region

11. North America Stem Cells Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product Type, 2017–2028

        11.2.1. Adult Stem Cell

        11.2.2. Human Embryonic Stem Cell

        11.2.3. Induced Pluripotent Stem Cell

        11.2.4. Others

    11.3. Market Value Forecast, by Source, 2017–2028

        11.3.1. Autologous

        11.3.2. Allogenic

    11.4. Market Value Forecast, by Application, 2017–2028

        11.4.1. Regenerative Medicines

            11.4.1.1. Neurology

            11.4.1.2. Oncology

            11.4.1.3. Cardiology

            11.4.1.4. Others

        11.4.2. Drug Discovery & Development

    11.5. Market Value Forecast, by End-user, 2017–2028

        11.5.1. Therapeutics Companies

        11.5.2. Cell & Tissue Banks

        11.5.3. Tools & Reagents Companies

        11.5.4. Service Companies

    11.6. Market Value Forecast, by Country, 2017–2028

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Product Type

        11.7.2. By Source

        11.7.3. By Application

        11.7.4. By End-user

        11.7.5. By Country

12. Europe Stem Cells Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product Type, 2017–2028

        12.2.1. Adult Stem Cell

        12.2.2. Human Embryonic Stem Cell

        12.2.3. Induced Pluripotent Stem Cell

        12.2.4. Others

    12.3. Market Value Forecast, by Source, 2017–2028

        12.3.1. Autologous

        12.3.2. Allogenic

    12.4. Market Value Forecast, by Application, 2017–2028

        12.4.1. Regenerative Medicines

            12.4.1.1. Neurology

            12.4.1.2. Oncology

            12.4.1.3. Cardiology

            12.4.1.4. Others

        12.4.2. Drug Discovery & Development

    12.5. Market Value Forecast, by End-user, 2017–2028

        12.5.1. Therapeutics Companies

        12.5.2. Cell & Tissue Banks

        12.5.3. Tools & Reagents Companies

        12.5.4. Service Companies

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2028

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Product Type

        12.7.2. By Source

        12.7.3. By Application

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Stem Cells Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product Type, 2017–2028

        13.2.1. Adult Stem Cell

        13.2.2. Human Embryonic Stem Cell

        13.2.3. Induced Pluripotent Stem Cell

        13.2.4. Others

    13.3. Market Value Forecast, by Source, 2017–2028

        13.3.1. Autologous

        13.3.2. Allogenic

    13.4. Market Value Forecast, by Application, 2017–2028

        13.4.1. Regenerative Medicines

            13.4.1.1. Neurology

            13.4.1.2. Oncology

            13.4.1.3. Cardiology

            13.4.1.4. Others

        13.4.2. Drug Discovery & Development

    13.5. Market Value Forecast, by End-user, 2017–2028

        13.5.1. Therapeutics Companies

        13.5.2. Cell & Tissue Banks

        13.5.3. Tools & Reagents Companies

        13.5.4. Service Companies

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2028

        13.6.1. Japan

        13.6.2. China

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of APAC

    13.7. Market Attractiveness Analysis

        13.7.1. By Product Type

        13.7.2. By Source

        13.7.3. By Application

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Latin America Stem Cells Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Product Type, 2017–2028

        14.2.1. Adult Stem Cell

        14.2.2. Human Embryonic Stem Cell

        14.2.3. Induced Pluripotent Stem Cell

        14.2.4. Others

    14.3. Market Value Forecast, by Source, 2017–2028

        14.3.1. Autologous

        14.3.2. Allogenic

    14.4. Market Value Forecast, by Application, 2017–2028

        14.4.1. Regenerative Medicines

            14.4.1.1. Neurology

            14.4.1.2. Oncology

            14.4.1.3. Cardiology

            14.4.1.4. Others

        14.4.2. Drug Discovery & Development

    14.5. Market Value Forecast, by End-user, 2017–2028

        14.5.1. Therapeutics Companies

        14.5.2. Cell & Tissue Banks

        14.5.3. Tools & Reagents Companies

        14.5.4. Service Companies

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2028

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of LATAM

    14.7. Market Attractiveness Analysis

        14.7.1. By Product Type

        14.7.2. By Source

        14.7.3. By Application

        14.7.4. By End-user

        14.7.5. By Country/Sub-region

15. Middle East & Africa Stem Cells Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Product Type, 2017–2028

        15.2.1. Adult Stem Cell

        15.2.2. Human Embryonic Stem Cell

        15.2.3. Induced Pluripotent Stem Cell

        15.2.4. Others

    15.3. Market Value Forecast, by Source, 2017–2028

        15.3.1. Autologous

        15.3.2. Allogenic

    15.4. Market Value Forecast, by Application, 2017–2028

        15.4.1. Regenerative Medicines

            15.4.1.1. Neurology

            15.4.1.2. Oncology

            15.4.1.3. Cardiology

            15.4.1.4. Others

        15.4.2. Drug Discovery & Development

    15.5. Market Value Forecast, by End-user, 2017–2028

        15.5.1. Therapeutics Companies

        15.5.2. Cell & Tissue Banks

        15.5.3. Tools & Reagents Companies

        15.5.4. Service Companies

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2028

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of MEA

    15.7. Market Attractiveness Analysis

        15.7.1. By Product Type

        15.7.2. By Source

        15.7.3. By Application

        15.7.4. By End-user

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Market Share/Ranking Analysis, by Company, 2020

    16.3. Company Profiles

        16.3.1. STEMCELL Technologies, Inc.

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Financial Overview

            16.3.1.3. Product Portfolio

            16.3.1.4. SWOT Analysis

            16.3.1.5. Strategic Overview

        16.3.2. Astellas Pharma, Inc.

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Financial Overview

            16.3.2.3. Product Portfolio

            16.3.2.4. SWOT Analysis

            16.3.2.5. Strategic Overview

        16.3.3. Cellular Engineering Technologies, Inc.

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Financial Overview

            16.3.3.3. Product Portfolio

            16.3.3.4. SWOT Analysis

            16.3.3.5. Strategic Overview

        16.3.4. BioTime, Inc.

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Financial Overview

            16.3.4.3. Product Portfolio

            16.3.4.4. SWOT Analysis

            16.3.4.5. Strategic Overview

        16.3.5. Takara Bio, Inc.

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Financial Overview

            16.3.5.3. Product Portfolio

            16.3.5.4. SWOT Analysis

            16.3.5.5. Strategic Overview

        16.3.6. U.S. Stem Cell, Inc.

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Financial Overview

            16.3.6.3. Product Portfolio

            16.3.6.4. SWOT Analysis

            16.3.6.5. Strategic Overview

        16.3.7. BrainStorm Cell Therapeutics, Inc.

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Financial Overview

            16.3.7.3. Product Portfolio

            16.3.7.4. SWOT Analysis

            16.3.7.5. Strategic Overview

        16.3.8. Cytori Therapeutics, Inc.

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Financial Overview

            16.3.8.3. Product Portfolio

            16.3.8.4. SWOT Analysis

            16.3.8.5. Strategic Overview

        16.3.9. Osiris Therapeutics, Inc.

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Financial Overview

            16.3.9.3. Product Portfolio

            16.3.9.4. SWOT Analysis

            16.3.9.5. Strategic Overview

        16.3.10. Caladrius Biosciences, Inc.

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Financial Overview

            16.3.10.3. Product Portfolio

            16.3.10.4. SWOT Analysis

            16.3.10.5. Strategic Overview

        16.3.11. Other Prominent Players